Source:http://linkedlifedata.com/resource/pubmed/id/11327783
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2001-4-30
|
| pubmed:abstractText |
Epstein-Barr virus (EBV) is a ubiquitous and highly immunotropic gamma herpesvirus that infects more than 90 % of humans worldwide. Its pathogenicity leads to a number of diseases including tumors that result from EBV's ability to readily transform B-lymphocytes and, to a lesser extent, epithelial cells. EBV utilizes CD21/CR2 as its receptor on B cells to initiate the infection process. EBV binds to CR2 through its major envelope glycoprotein-350 (gp350) and is also a remarkable immunomodulating agent. We had previously shown that EBV is capable of modulating the synthesis of a number of cytokines. We now show that while both purified recombinant gp350 (rgp350) and EBV upregulate IL-6 mRNA synthesis in B cells, EBV-induced IL-6 gene activation occurs for a significantly longer period of time (i.e. 12 hours for EBV as compared to 6 hours for rgp350). Moreover, the half-life of EBV-induced IL-6 mRNA was also significantly longer (10 hours) than that of mRNA induced by rgp350 (about 6 hours). Both EBV and gp350 enhance the binding of the NF-kappaB transcription factor, as determined by band-shift and augment NF-kappaB-mediated activation of a CAT reporter plasmid. Furthermore, we demonstrate that while the activation of IL-6 gene expression by gp350 is mediated primarily by the protein kinase C pathway, EBV can mediate its effects through multiple signaling pathways. To our knowledge this is the first report showing that the binding of a herpesvirus envelope glycoprotein to CR2 on human B cells results in the activation of the NF-kappaB transcription factor leading to the upregulation of IL-6 gene expression in these lymphocytes.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CCAAT-Enhancer-Binding Protein-beta,
http://linkedlifedata.com/resource/pubmed/chemical/DNA,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/GP 300-350, Epstein-Barr virus,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/NF-kappa B,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase C,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Complement 3d,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Virus,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Matrix Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0022-2836
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2001 Academic Press.
|
| pubmed:issnType |
Print
|
| pubmed:day |
4
|
| pubmed:volume |
308
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
501-14
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:11327783-B-Lymphocytes,
pubmed-meshheading:11327783-CCAAT-Enhancer-Binding Protein-beta,
pubmed-meshheading:11327783-Cells, Cultured,
pubmed-meshheading:11327783-DNA,
pubmed-meshheading:11327783-Enzyme Inhibitors,
pubmed-meshheading:11327783-Half-Life,
pubmed-meshheading:11327783-Herpesvirus 4, Human,
pubmed-meshheading:11327783-Humans,
pubmed-meshheading:11327783-Interleukin-6,
pubmed-meshheading:11327783-Membrane Glycoproteins,
pubmed-meshheading:11327783-NF-kappa B,
pubmed-meshheading:11327783-Promoter Regions, Genetic,
pubmed-meshheading:11327783-Protein Binding,
pubmed-meshheading:11327783-Protein Kinase C,
pubmed-meshheading:11327783-RNA, Messenger,
pubmed-meshheading:11327783-RNA Stability,
pubmed-meshheading:11327783-Receptors, Complement 3d,
pubmed-meshheading:11327783-Receptors, Virus,
pubmed-meshheading:11327783-Response Elements,
pubmed-meshheading:11327783-Signal Transduction,
pubmed-meshheading:11327783-Transcriptional Activation,
pubmed-meshheading:11327783-Transfection,
pubmed-meshheading:11327783-Up-Regulation,
pubmed-meshheading:11327783-Viral Matrix Proteins
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
|
| pubmed:affiliation |
Laboratory of Immunovirology, Department of Microbiology and Immunology and Pediatric Research Center, University of Montreal, and Ste. Justine Hospital, 3175 Côte Ste. Catherine, Montreal, Quebec H3T 1C5, Canada.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|